University of Oxford

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.

Llusern Scientific has received ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform that delivers lab-accurate UTI results in approximately 30 minutes.

A randomized controlled trial of 161 patients with major depressive disorder and obesity found that adding simvastatin to escitalopram provided no additional antidepressant benefits compared to placebo.

The University of Oxford and ReciBioPharm have expanded their collaboration to manufacture two blood-stage malaria vaccine candidates, R78C and RH5.1, for Phase 1/2 clinical trials.

LivaNova's comprehensive CORE-VNS study of over 800 patients worldwide demonstrates sustained effectiveness of VNS Therapy for drug-resistant epilepsy over 36 months.

A University of Oxford analysis of 11 studies found patients regain all lost weight within 10 months after stopping older GLP-1 medications and within 20 months for newer drugs like Wegovy and Mounjaro.

A groundbreaking University of Oxford study reveals that prior cytomegalovirus (CMV) infection improves melanoma patients' response to single-drug PD-1 immunotherapy while reducing severe side effects.

Circle Pharma will present late-breaking data at AACR 2025 showing how their novel cyclin A/B RxL inhibitors disrupt DNA repair pathways and affect mitotic progression in E2F-high cancers.